Press release: Available for immediate release
The MPN Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in myeloproliferative neoplasms (MPN). During the first quarter of 2022, we continued to promote significant developments in the treatment of MPN through coverage of a prominent congress.
In March, the MPN Hub virtually attended the 48th Annual Meeting of the EBMT, where we provided live updates on social media, conducted expert interviews, and developed congress-related summary articles for our audience. This activity contributed to the hub receiving over 20,000 page views and just over 4,400 visitors during Q1, as well as 37,000 impressions on our social channels.
During Q1, the MPN Hub also published two visual abstracts. The first summarized key efficacy and safety results from the phase II REFINE trial, in which navitoclax was added to ruxolitinib in patients with myelofibrosis. The second presented results from the phase II FIGHT-203 study, evaluating the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Reviewing the MPN Hub’s impact this quarter, Gizem Karakuleli, MPN Hub Content Lead at Scientific Education Support, said:
“We were delighted to virtually attend the 48th Annual Meeting of the EBMT, where our team provided extensive coverage and reviewed some of the latest treatment and research areas of interest for the MPN community. Having a dedicated team at this virtual event allowed us to provide our audience with live congress commentary on the latest insights and findings in the field. Our coverage for the event performed especially well on our social channels, where we focussed on outcomes of cellular therapy in different types of MPN, such as blast phase MPN and chronic neutrophilic leukemia.
“As part of our commitment to continuously enhance the hub’s user experience, we have introduced new digital innovations, including article learning objectives and interactive quizzes, which test a user’s pre- and post-knowledge when reading an article. We have also updated the hub with Google Translate, and as a result, the content can be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.
“We would like to thank the MPN Hub Steering Committee and our supporters—Bristol Myers Squibb, AbbVie, CTI BioPharma, Novartis, Kartos Therapeutics, AOP Orphan, Constellation Pharmaceuticals, Geron, and Sierra Oncology—without whom our work would not be possible.”
For more information on the MPN Hub, please visit mpn-hub.com.
For media enquiries or to explore opportunities for collaboration, please contact email@example.com or Barry.Connolly@scientificeducationsupport.com.
About myeloproliferative neoplasms (MPN)
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers where the body produces too many red blood cells, white blood cells, or platelets. The three main types include myelofibrosis, polycythemia vera, and essential thrombocythemia.
About the MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge of MPN through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MPN Hub supports HCPs worldwide.
Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MPN Hub is guided by an international steering committee of experts in the field of MPN. The steering committee meet regularly to discuss the performance of the MPN Hub and to devise action plans on how best to support the MPN community and address any unmet educational needs.
Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.
- Bristol Myers Squibb
- CTI BioPharma
- Kartos Therapeutics
- AOP Orphan
- Constellation Pharmaceuticals
- Sierra Oncology
If you are interested in becoming an MPN Hub supporter, please contact firstname.lastname@example.org.
About Scientific Education Support (SES)
SES is a medical education company providing projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through the Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hematological-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and Multiple Myeloma Hub.
About The European LeukemiaNet
220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.